Astrocyte-specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor

GLIA

Volumn 62, Issue 2, 2014, Pages 272-283

  Fischer, Roman ^a   Wajant, Harald ^b   Kontermann, Roland ^a   Pfizenmaier, Klaus ^a   Maier, Olaf ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Astrocytes; Myelination; Oligodendrocytes; TNFR2

Indexed keywords

LEUKEMIA INHIBITORY FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GLIA CELL; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; MOUSE; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA ISOLATION; SIGNAL TRANSDUCTION;

ASTROCYTES; MYELINATION; OLIGODENDROCYTES; TNFR2;

ANIMALS; ASTROCYTES; CELL DIFFERENTIATION; CELL LINE; CELLS, CULTURED; HUMANS; LEUKEMIA INHIBITORY FACTOR; MICE; MICE, INBRED C57BL; OLIGODENDROGLIA; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; STEM CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890168870     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22605     Document Type: Article

References (49)

1. Ameloot P, Fiers W, De Bleser P, Ware CF, Vandenabeele P, Brouckaert P. 2001. Identification of tumor necrosis factor (TNF) amino acids crucial for binding to the murine p75 TNF receptor and construction of receptor-selective mutants. J Biol Chem 276:37426-37430.
2. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. 2001. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4:1116-1122.
3. Barres BA, Schmid R, Sendnter M, Raff MC. 1993. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development 118:283-295.
4. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, Ambrose C, Tschopp J, Schneider P. 2006. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 281:13964-13971.
5. Butzkueven H, Emery B, Cipriani T, Marriott MP, Kilpatrick TJ. 2006. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia 53:696-703.
6. Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA, Emery B, Turnley AM, Petratos S, Ernst M and others. 2002. LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat Med 8:613-619.
7. Carlson T, Kroenke M, Rao P, Lane TE, Segal B. 2008. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med 205:811-823.
8. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA, Chang JH, Lindquist RA, Moffat J and others. 2006. CellProfiler: Image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7:R100.
9. Daginakatte GC, Gadzinski A, Emnett RJ, Stark JL, Gonzales ER, Yan P, Lee JM, Cross AH, Gutmann DH. 2008. Expression profiling identifies a molecular signature of reactive astrocytes stimulated by cyclic AMP or proinflammatory cytokines. Exp Neurol 210:261-267.
10. Deverman BE, Patterson PH. 2012. Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and enhances hippocampal remyelination. J Neurosci 32:2100-2109.
11. Dolga AM, Granic I, Blank T, Knaus HG, Spiess J, Luiten PG, Eisel UL, Nijholt IM. 2008. TNF-alpha-mediates neuroprotection against glutamate-induced excitotoxicity via NF-kappaB-dependent up-regulation of K2.2 channels. J Neurochem 107:1158-1167.
12. Douni E, Kollias G. 1998. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. J Exp Med 188:1343-1352.
13. Fischer R, Maier O, Naumer M, Krippner-Heidenreich A, Scheurich P, Pfizenmaier K. 2011a. Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFkappaB pathway. Cell Signal 23:161-170.
14. Fischer R, Maier O, Siegemund M, Wajant H, Scheurich P, Pfizenmaier K. 2011b. A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS One 6:e27621.
15. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. 2002. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: Opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 22:RC216.
16. Gresle MM, Alexandrou E, Wu Q, Egan G, Jokubaitis V, Ayers M, Jonas A, Doherty W, Friedhuber A, Shaw G and others. 2012. Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte-independent mechanism. PLoS One 7:e47379.
17. Haroon F, Drogemuller K, Handel U, Brunn A, Reinhold D, Nishanth G, Mueller W, Trautwein C, Ernst M, Deckert M and others. 2011. Gp130-dependent astrocytic survival is critical for the control of autoimmune central nervous system inflammation. J Immunol 186:6521-6531.
18. Hofman FM, Hinton DR, Johnson K, Merrill JE. 1989. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 170:607-612.
19. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, Fields RD. 2006. Astrocytes promote myelination in response to electrical impulses. Neuron 49:823-832.
20. Kahn MA, De Vellis J. 1994. Regulation of an oligodendrocyte progenitor cell line by the interleukin-6 family of cytokines. Glia 12:87-98.
21. Kerr BJ, Patterson PH. 2004. Potent pro-inflammatory actions of leukemia inhibitory factor in the spinal cord of the adult mouse. Exp Neurol 188:391-407.
22. Kerr BJ, Patterson PH. 2005. Leukemia inhibitory factor promotes oligodendrocyte survival after spinal cord injury. Glia 51:73-79.
23. Lassmann H, Bruck W, Lucchinetti CF. 2007. The immunopathology of multiple sclerosis: An overview. Brain Pathol 17:210-218.
24. Lenercept. 1999. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53:457-465.
25. Lewis M, Tartaglia LA, Lee A, Bennett GL, Rice GC, Wong GH, Chen EY, Goeddel DV. 1991. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci U S A 88:2830-2834.
26. Maier O, Fischer R, Agresti C, Pfizenmaier K. 2013. TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress. Biochem Biophys Res Commun., 440:336-341.
27. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL. 2004. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-d-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem 279:32869-32881.
28. Mason JL, Suzuki K, Chaplin DD, Matsushima GK. 2001. Interleukin-1beta promotes repair of the CNS. J Neurosci 21:7046-7052.
29. Mayer M, Bhakoo K, Noble M. 1994. Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. Development 120:143-153.
30. McCoy MK, Tansey MG. 2008. TNF signaling inhibition in the CNS: Implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5:45.
31. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. 2001. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44:2862-2869.
32. Nair A, Frederick TJ, Miller SD. 2008. Astrocytes in multiple sclerosis: A product of their environment. Cell Mol Life Sci 65:2702-2720.
33. Norton WT, Aquino DA, Hozumi I, Chiu FC, Brosnan CF. 1992. Quantitative aspects of reactive gliosis: A review. Neurochem Res 17:877-885.
34. Omari KM, John G, Lango R, Raine CS. 2006. Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 53:24-31.
35. Omari KM, John GR, Sealfon SC, Raine CS. 2005. CXC chemokine receptors on human oligodendrocytes: Implications for multiple sclerosis. Brain 128(Pt 5):1003-1015.
36. Omari KM, Lutz SE, Santambrogio L, Lira SA, Raine CS. 2009. Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1. Am J Pathol 174:164-176.
37. Park SK, Solomon D, Vartanian T. 2001. Growth factor control of CNS myelination. Dev Neurosci 23(4-5):327-337.
38. Patel JR, McCandless EE, Dorsey D, Klein RS. 2010. CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination. Proc Natl Acad Sci USA 107:11062-11067.
39. Patel JR, Williams JL, Muccigrosso MM, Liu L, Sun T, Rubin JB, Klein RS. 2012. Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation within the adult CNS. Acta Neuropathol 124:847-860.
40. Pfizenmaier K, Szymkowski DE. 2011. Workshop summary: Introduction to rational design of new means for therapeutic modulation of function of the TNF family. Adv Exp Med Biol 691:487-491.
41. Ranges GE, Bombara MP, Aiyer RA, Rice GG, Palladino MA, Jr. 1989. Tumor necrosis factor-alpha as a proliferative signal for an IL-2-dependent T cell line: Strict species specificity of action. J Immunol 142:1203-1208.
42. Rauert H, Wicovsky A, Muller N, Siegmund D, Spindler V, Waschke J, Kneitz C, Wajant H. 2010. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J Biol Chem 285:7394-7404.
43. Schonrock LM, Gawlowski G, Bruck W. 2000. Interleukin-6 expression in human multiple sclerosis lesions. Neurosci Lett 294:45-48.
44. Sharief MK, Hentges R. 1991. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467-472.
45. Stankoff B, Aigrot MS, Noel F, Wattilliaux A, Zalc B, Lubetzki C. 2002. Ciliary neurotrophic factor (CNTF) enhances myelin formation: A novel role for CNTF and CNTF-related molecules. J Neurosci 22:9221-9227.
46. Sugiura S, Lahav R, Han J, Kou SY, Banner LR, de Pablo F, Patterson PH. 2000. Leukaemia inhibitory factor is required for normal inflammatory responses to injury in the peripheral and central nervous systems in vivo and is chemotactic for macrophages in vitro. Eur J Neurosci 12:457-466.
47. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. 1996. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531-1534.
48. Vanderlocht J, Hellings N, Hendriks JJ, Vandenabeele F, Moreels M, Buntinx M, Hoekstra D, Antel JP, Stinissen P. 2006. Leukemia inhibitory factor is produced by myelin-reactive T cells from multiple sclerosis patients and protects against tumor necrosis factor-alpha-induced oligodendrocyte apoptosis. J Neurosci Res 83:763-774.
49. Williams A, Piaton G, Lubetzki C. 2007. Astrocytes-Friends or foes in multiple sclerosis? Glia 55:1300-1312.